282 related articles for article (PubMed ID: 26581135)
1. Phase 2 Trial of De-intensified Chemoradiation Therapy for Favorable-Risk Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma.
Chera BS; Amdur RJ; Tepper J; Qaqish B; Green R; Aumer SL; Hayes N; Weiss J; Grilley-Olson J; Zanation A; Hackman T; Funkhouser W; Sheets N; Weissler M; Mendenhall W
Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):976-85. PubMed ID: 26581135
[TBL] [Abstract][Full Text] [Related]
2. Mature results of a prospective study of deintensified chemoradiotherapy for low-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma.
Chera BS; Amdur RJ; Tepper JE; Tan X; Weiss J; Grilley-Olson JE; Hayes DN; Zanation A; Hackman TG; Patel S; Sheets N; Weissler MC; Mendenhall WM
Cancer; 2018 Jun; 124(11):2347-2354. PubMed ID: 29579339
[TBL] [Abstract][Full Text] [Related]
3. Phase II Trial of De-Intensified Chemoradiotherapy for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma.
Chera BS; Amdur RJ; Green R; Shen C; Gupta G; Tan X; Knowles M; Fried D; Hayes N; Weiss J; Grilley-Olson J; Patel S; Zanation A; Hackman T; Zevallos J; Blumberg J; Patel S; Kasibhatla M; Sheets N; Weissler M; Yarbrough W; Mendenhall W
J Clin Oncol; 2019 Oct; 37(29):2661-2669. PubMed ID: 31411949
[TBL] [Abstract][Full Text] [Related]
4. Dosimetric Predictors of Patient-Reported Xerostomia and Dysphagia With Deintensified Chemoradiation Therapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma.
Chera BS; Fried D; Price A; Amdur RJ; Mendenhall W; Lu C; Das S; Sheets N; Marks L; Mavroidis P
Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1022-1027. PubMed ID: 28721884
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Patient- and Practitioner-Reported Toxic Effects Associated With Chemoradiotherapy for Head and Neck Cancer.
Falchook AD; Green R; Knowles ME; Amdur RJ; Mendenhall W; Hayes DN; Grilley-Olson JE; Weiss J; Reeve BB; Mitchell SA; Basch EM; Chera BS
JAMA Otolaryngol Head Neck Surg; 2016 Jun; 142(6):517-23. PubMed ID: 27149571
[TBL] [Abstract][Full Text] [Related]
6. Dose-volume toxicity modeling for de-intensified chemo-radiation therapy for HPV-positive oropharynx cancer.
Mavroidis P; Price A; Fried D; Kostich M; Amdur R; Mendenhall W; Liu C; Das S; Marks LB; Chera B
Radiother Oncol; 2017 Aug; 124(2):240-247. PubMed ID: 28712533
[TBL] [Abstract][Full Text] [Related]
7. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.
Gillison ML; Trotti AM; Harris J; Eisbruch A; Harari PM; Adelstein DJ; Jordan RCK; Zhao W; Sturgis EM; Burtness B; Ridge JA; Ringash J; Galvin J; Yao M; Koyfman SA; Blakaj DM; Razaq MA; Colevas AD; Beitler JJ; Jones CU; Dunlap NE; Seaward SA; Spencer S; Galloway TJ; Phan J; Dignam JJ; Le QT
Lancet; 2019 Jan; 393(10166):40-50. PubMed ID: 30449625
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 study of docetaxel, cisplatin, and concurrent radiation for technically resectable stage III-IV squamous cell carcinoma of the head and neck.
Inohara H; Takenaka Y; Yoshii T; Nakahara S; Yamamoto Y; Tomiyama Y; Seo Y; Isohashi F; Suzuki O; Yoshioka Y; Sumida I; Ogawa K
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):934-41. PubMed ID: 25832686
[TBL] [Abstract][Full Text] [Related]
9. OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer.
Seiwert TY; Foster CC; Blair EA; Karrison TG; Agrawal N; Melotek JM; Portugal L; Brisson RJ; Dekker A; Kochanny S; Gooi Z; Lingen MW; Villaflor VM; Ginat DT; Haraf DJ; Vokes EE
Ann Oncol; 2019 Feb; 30(2):297-302. PubMed ID: 30481287
[TBL] [Abstract][Full Text] [Related]
10. Phase II Evaluation of Aggressive Dose De-Escalation for Adjuvant Chemoradiotherapy in Human Papillomavirus-Associated Oropharynx Squamous Cell Carcinoma.
Ma DJ; Price KA; Moore EJ; Patel SH; Hinni ML; Garcia JJ; Graner DE; Foster NR; Ginos B; Neben-Wittich M; Garces YI; Chintakuntlawar AV; Price DL; Olsen KD; Van Abel KM; Kasperbauer JL; Janus JR; Waddle M; Miller R; Shiraishi S; Foote RL
J Clin Oncol; 2019 Aug; 37(22):1909-1918. PubMed ID: 31163012
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.
Mehanna H; Robinson M; Hartley A; Kong A; Foran B; Fulton-Lieuw T; Dalby M; Mistry P; Sen M; O'Toole L; Al Booz H; Dyker K; Moleron R; Whitaker S; Brennan S; Cook A; Griffin M; Aynsley E; Rolles M; De Winton E; Chan A; Srinivasan D; Nixon I; Grumett J; Leemans CR; Buter J; Henderson J; Harrington K; McConkey C; Gray A; Dunn J;
Lancet; 2019 Jan; 393(10166):51-60. PubMed ID: 30449623
[TBL] [Abstract][Full Text] [Related]
12. Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: Assessment from a phase 3 registration trial.
Bonner JA; Giralt J; Harari PM; Baselga J; Spencer S; Bell D; Raben D; Liu J; Schulten J; Ang KK; Rosenthal DI
Eur J Cancer; 2016 Sep; 64():1-11. PubMed ID: 27323346
[TBL] [Abstract][Full Text] [Related]
13. Functional Outcomes After De-escalated Chemoradiation Therapy for Human Papillomavirus-Positive Oropharyngeal Cancer: Secondary Analysis of a Phase 2 Trial.
Hegde JV; Shaverdian N; Felix C; Wang PC; Veruttipong D; Hsu S; Riess JW; Rao SD; Daly ME; Chen AM
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):647-651. PubMed ID: 29246721
[TBL] [Abstract][Full Text] [Related]
14. Selective Treatment Deintensification by Reducing Radiation Dose and Omitting Concurrent Chemotherapy Based on Response to Induction Chemotherapy in Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma: A Single-Arm, Phase 2 Trial (IChoice-01).
Xu T; Shen C; Zhou X; Zhu L; Xiang J; Wang Y; Zhu Y; He X; Ying H; Wang Y; Ji Q; Hu C; Lu X
Int J Radiat Oncol Biol Phys; 2024 Jan; 118(1):169-178. PubMed ID: 37574169
[TBL] [Abstract][Full Text] [Related]
15. Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311).
Ferris RL; Flamand Y; Weinstein GS; Li S; Quon H; Mehra R; Garcia JJ; Chung CH; Gillison ML; Duvvuri U; O'Malley BW; Ozer E; Thomas GR; Koch WM; Gross ND; Bell RB; Saba NF; Lango M; Méndez E; Burtness B
J Clin Oncol; 2022 Jan; 40(2):138-149. PubMed ID: 34699271
[TBL] [Abstract][Full Text] [Related]
16. Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002).
Yom SS; Torres-Saavedra P; Caudell JJ; Waldron JN; Gillison ML; Xia P; Truong MT; Kong C; Jordan R; Subramaniam RM; Yao M; Chung CH; Geiger JL; Chan JW; O'Sullivan B; Blakaj DM; Mell LK; Thorstad WL; Jones CU; Banerjee RN; Lominska C; Le QT
J Clin Oncol; 2021 Mar; 39(9):956-965. PubMed ID: 33507809
[TBL] [Abstract][Full Text] [Related]
17. Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study.
Chen AM; Felix C; Wang PC; Hsu S; Basehart V; Garst J; Beron P; Wong D; Rosove MH; Rao S; Melanson H; Kim E; Palmer D; Qi L; Kelly K; Steinberg ML; Kupelian PA; Daly ME
Lancet Oncol; 2017 Jun; 18(6):803-811. PubMed ID: 28434660
[TBL] [Abstract][Full Text] [Related]
18. E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group.
Marur S; Li S; Cmelak AJ; Gillison ML; Zhao WJ; Ferris RL; Westra WH; Gilbert J; Bauman JE; Wagner LI; Trevarthen DR; Balkrishna J; Murphy BA; Agrawal N; Colevas AD; Chung CH; Burtness B
J Clin Oncol; 2017 Feb; 35(5):490-497. PubMed ID: 28029303
[TBL] [Abstract][Full Text] [Related]
19. Helical intensity-modulated radiotherapy with concurrent chemotherapy for oropharyngeal squamous cell carcinoma: A prospective investigation of acute swallowing and toxicity patterns.
Moroney LB; Helios J; Ward EC; Crombie J; Pelecanos A; Burns CL; Spurgin AL; Blake C; Kenny L; Chua B; Hughes BGM
Head Neck; 2018 Sep; 40(9):1955-1966. PubMed ID: 29756244
[TBL] [Abstract][Full Text] [Related]
20. Intensified intensity-modulated radiotherapy in anal cancer with prevalent HPV p16 positivity.
Belgioia L; Vagge S; Agnese D; Garelli S; Murialdo R; Fornarini G; Chiara S; Gallo F; Bacigalupo A; Corvò R
World J Gastroenterol; 2015 Oct; 21(37):10688-96. PubMed ID: 26457030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
